JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%Zhitong·Oct 29, 2025 at 11:11 AM300529+0.38%
JAFRON: The extracorporeal circulation blood pathway of the blood purification device has obtained EU MDR certificationZhitong·Jun 18, 2025 at 05:20 AM300529+0.38%
JAFRON released its first-quarter performance, with a net profit attributable to the parent company of 189 million yuan, a year-on-year decrease of 33.71%Zhitong·Apr 15, 2025 at 08:04 AM300529+0.38%
JAFRON released its 2024 annual performance, with a net profit attributable to shareholders of 820 million yuan, a year-on-year increase of 87.91%Zhitong·Apr 15, 2025 at 07:52 AM300529+0.38%
Jafron Biomedical Co.,Ltd. (SZSE:300529) insiders have significant skin in the game with 51% ownershipSimplywall·Mar 16, 2025 at 10:16 PM300529+0.38%
JAFRON expects a profit increase, with an estimated annual net profit of 800 million to 860 million yuan, a year-on-year growth of 83% to 97%Zhitong·Jan 21, 2025 at 07:23 AM300529+0.38%
JAFRON: Net profit in 2024 is expected to increase by 83% to 97% year-on-yearUSHK News·Jan 21, 2025 at 05:20 AM300529+0.38%
